Jounce Therapeutics (Jounce Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics 3-Year Dividend Growth Rate?

Jounce Therapeutics's Dividends per Share for the three months ended in Dec. 2022 was $0.00.

The historical rank and industry rank for Jounce Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

JNCE's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Jounce Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2022 was 0.00. As of today, Jounce Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Jounce Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Jounce Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jounce Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jounce Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Jounce Therapeutics's 3-Year Dividend Growth Rate falls into.

Jounce Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Jounce Therapeutics (NAS:JNCE) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Jounce Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2022 )	/	EPS without NRI (Q: Dec. 2022 )
	=	0	/	0.98
	=	0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jounce Therapeutics 3-Year Dividend Growth Rate Related Terms>

Jounce Therapeutics (Jounce Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.jouncetx.com

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Executives

Concentra Merger Sub, Inc.	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray	director, officer: CEO and President	22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole	officer: Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu	officer: Chief Medical Officer	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin	officer: CFO and Treasurer	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons	director	C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid	director	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404